These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28364292)

  • 1. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
    Sesar Á; Fernández-Pajarín G; Ares B; Rivas MT; Castro A
    J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
    Sesar Á; Fernández-Pajarín G; Ares B; Relova JL; Arán E; Rivas MT; Gelabert-González M; Castro A
    J Neurol; 2019 Mar; 266(3):659-666. PubMed ID: 30617907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.
    Drapier S; Gillioz AS; Leray E; Péron J; Rouaud T; Marchand A; Vérin M
    Parkinsonism Relat Disord; 2012 Jan; 18(1):40-4. PubMed ID: 21890396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Lockhart D; Staines H; Lees A
    Parkinsonism Relat Disord; 2021 Feb; 83():79-85. PubMed ID: 33486139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study.
    Fernández-Pajarín G; Sesar Á; Ares B; Castro A
    J Parkinsons Dis; 2016 Oct; 6(4):787-792. PubMed ID: 27662329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F
    Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
    Bhidayasiri R; Sringean J; Anan C; Boonpang K; Thanawattano C; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S36-S41. PubMed ID: 27939326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
    Alegret M; Valldeoriola F; Martí M; Pilleri M; Junqué C; Rumià J; Tolosa E
    Mov Disord; 2004 Dec; 19(12):1463-9. PubMed ID: 15390065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
    Borgemeester RW; Drent M; van Laar T
    Parkinsonism Relat Disord; 2016 Feb; 23():17-22. PubMed ID: 26709292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect.
    Martinez-Martin P; Reddy P; Antonini A; Henriksen T; Katzenschlager R; Odin P; Todorova A; Naidu Y; Tluk S; Chandiramani C; Martin A; Chaudhuri KR
    J Parkinsons Dis; 2011; 1(2):197-203. PubMed ID: 23934921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.